Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-blind eleclazine study in congenital long QT syndrome type 3
NL-OMON41816Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of eleclazine in Long QT Syndrome Type 3 (LQT3) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Change in mean daytime QTcF interval at Week 24 and Safety and tolerability. Started Aug 2015; status: active, not recruiting.
02
Drugs
eleclazine
03
Conditions
Long QT Syndrome Type 3 (LQT3)
Beyond the preview
Go deeper on NL-OMON41816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41816.